Fenton RG - Search Results

1

Partitioning apoptosis: a novel form of the execution phase of apoptosis.

Zhang B, Arany Z, Mann D, Rhee JG, Fenton RG. Zhang B, et al. Among authors: fenton rg. Apoptosis. 2005 Jan;10(1):219-31. doi: 10.1007/s10495-005-6077-4. Apoptosis. 2005. PMID: 15711938

2

Myeloid cell factor-1 is a critical survival factor for multiple myeloma.

Zhang B, Gojo I, Fenton RG. Zhang B, et al. Among authors: fenton rg. Blood. 2002 Mar 15;99(6):1885-93. doi: 10.1182/blood.v99.6.1885. Blood. 2002. PMID: 11877256 Free article.

3

Proliferation of IL-6-independent multiple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2).

Zhang B, Fenton RG. Zhang B, et al. Among authors: fenton rg. J Cell Physiol. 2002 Oct;193(1):42-54. doi: 10.1002/jcp.10148. J Cell Physiol. 2002. PMID: 12209879

4

The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.

Gojo I, Zhang B, Fenton RG. Gojo I, et al. Among authors: fenton rg. Clin Cancer Res. 2002 Nov;8(11):3527-38. Clin Cancer Res. 2002. PMID: 12429644

5

IL-6-independent expression of Mcl-1 in human multiple myeloma.

Zhang B, Potyagaylo V, Fenton RG. Zhang B, et al. Among authors: fenton rg. Oncogene. 2003 Mar 27;22(12):1848-59. doi: 10.1038/sj.onc.1206358. Oncogene. 2003. PMID: 12660820

6

Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.

Zhang B, Prendergast GC, Fenton RG. Zhang B, et al. Among authors: fenton rg. Cancer Res. 2002 Jan 15;62(2):450-8. Cancer Res. 2002. PMID: 11809695

7

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.

Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Badros AZ, et al. Among authors: fenton rg. J Clin Oncol. 2005 Jun 20;23(18):4089-99. doi: 10.1200/JCO.2005.14.381. Epub 2005 May 2. J Clin Oncol. 2005. PMID: 15867202 Clinical Trial.

8

Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.

Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G. Takebe N, et al. Among authors: fenton rg. Clin Cancer Res. 2004 Dec 15;10(24):8301-8. doi: 10.1158/1078-0432.CCR-04-0747. Clin Cancer Res. 2004. PMID: 15623606 Clinical Trial.

9

Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.

Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C, Ruehle K, Westphal S, Meisenberg B. Badros A, et al. Clin Lymphoma Myeloma. 2006 Nov;7(3):210-6. doi: 10.3816/CLM.2006.n.061. Clin Lymphoma Myeloma. 2006. PMID: 17229337 Clinical Trial.

10

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Badros A, et al. J Clin Oncol. 2006 Feb 20;24(6):945-52. doi: 10.1200/JCO.2005.04.2465. J Clin Oncol. 2006. PMID: 16484704

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters